Table 2.
Clinical features of patients with ERBB2 somatic mutations or ERBB2 amplification only in Geneplus cohort
| Characteristics | ERBB2 oncogenic mutationa (n = 474) | ERBB2 amplification only (n = 175) | P value |
|---|---|---|---|
| Age, years | <0.01 | ||
| Mean (SD) | 53.6 (12.8) | 63.0 (9.5) | |
| Median (min-max) | 54 (21-83) | 63 (37-89) | |
| Gender, n (%) | <0.001 | ||
| Male | 163 (34.4) | 120 (68.6) | |
| Female | 311 (65.6) | 55 (31.4) | |
| Smoking, n (%) | <0.001 | ||
| Never | 222 (78.7) | 58 (49.6) | |
| Ever | 60 (21.3) | 59 (50.4) | |
| Unknown | 192 (100) | 58 (100) | |
| Tumor stage, n (%) | 0.04b | ||
| I | 34 (23.8) | 5 (6.8) | |
| II | 6 (4.2) | 5 (6.8) | |
| III | 19 (13.3) | 9 (12.4) | |
| IV | 84 (58.7) | 54 (74.0) | |
| Unknown | 331 (100) | 102 | |
| Histology, n (%) | <0.001c | ||
| Adenocarcinoma | 412 (98.6) | 123 (82.6) | |
| Squamous cell carcinoma | 3 (0.7) | 23 (15.4) | |
| Adenosquamous carcinoma | 2 (0.5) | 2 (1.3) | |
| Sarcomatoid carcinoma | 1 (0.2) | 0 | |
| Neuroendocrine neoplasms | 0 | 1 (0.7) | |
| Unknown | 56 (100) | 26 | |
| Germline mutation, n (%) | 0.8 | ||
| Yes | 14 (3.0) | 6 (3.4) | |
| No | 460 (97.0) | 169 (96.6) | |
| PD-L1 test, n (%) | 0.8 | ||
| TPS < 1% | 54 (63.5) | 34 (58.6) | |
| TPS,1%-50% | 26 (30.6) | 19 (32.8) | |
| TPS ≥ 50% | 5 (5.9) | 5 (8.6) | |
| Unknown | 389 (100) | 117 (100) | |
| TMB | <0.001 | ||
| Mean (SD) | 3.5 (4.6) | 8.9 (9.2) | |
| Median (min-max) | 1.9 (0-28.8) | 5.8 (0-68.0) |
aERBB2 oncogenic mutation includes ERBB2 oncogenic mutation accompanied with/without ERBB2 amplification.
bComparison between I-III and IV.
cComparison between adenocarcinoma and non-adenocarcinoma.